carmustine + cisplatin + cyclophosphamide + doxorubicin + fluorouracil + methotrexate

This is a multi-agent chemotherapy combination consisting of six cytotoxic drugs: carmustine, cisplatin, cyclophosphamide, doxorubicin, fluorouracil (5-FU), and methotrexate. Each component has a distinct mechanism of action targeting cancer cells through different pathways: - Carmustine is an alkylating agent that cross-links DNA and RNA, inhibiting replication and transcription. - Cisplatin forms DNA adducts leading to apoptosis. - Cyclophosphamide is an alkylating agent that interferes with DNA replication. - Doxorubicin intercalates into DNA and inhibits topoisomerase II activity. - Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - Methotrexate inhibits dihydrofolate reductase, blocking folic acid metabolism required for nucleotide synthesis. Such combinations are designed to maximize anti-tumor efficacy by attacking cancer cells at multiple points in the cell cycle and reducing the likelihood of drug resistance. While each subset of these drugs appears in established regimens for various cancers (e.g., CAF for breast cancer; CMF for breast cancer; MVAC or PIAF for bladder or liver cancers), this exact six-drug combination does not correspond to a widely recognized named regimen but represents an intensive polychemotherapy approach potentially used in investigational settings or as salvage therapy[3][4][5][7][9].